Hormonal and natural contraceptives: a review on efficacy and risks of different methods for an informed choice

References

• Christin-Maitre S. History of oral contraceptive drugs and their use worldwide. Best Pract Res Clin Endocrinol Metab. 2013;27(1):1–13. doi: 10.1016/j.beem.2012.11.004 23384741
   PubMed Web of Science ®Google Scholar
• Pincus G, Rock J, Garcia C-R, et al. Fertility control with oral medication. Am J Obstet Gynecol. 1958;75(6):1–13. doi: 10.1016/0002-9378(58)90722-1.
   PubMed Web of Science ®Google Scholar
• United Nations . Contraceptive use by method 2019: data booklet. In: United Nations: UN-iLibrary; 2019
   Google Scholar
• Le Guen M, Schantz C, Régnier-Loilier A, et al. Reasons for rejecting hormonal contraception in Western countries: a systematic review. Soc Sci Med. 2021;284:114247. doi: 10.1016/J.SOCSCIMED.2021.114247.
   PubMed Web of Science ®Google Scholar
• Survival of the Richest. Oxfam International. https://www.oxfam.org/en/research/survival-richest. Accessed 8 Jul 2023
   Google Scholar
• Perico G. Stupro, aborto e anticoncezionali. In: civiltà cattolica; 1993. p. 37–46
   Google Scholar
• Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82(6):454–461.
   PubMed Web of Science ®Google Scholar
• Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: a review of the literature. Eur J Contracept Reprod Health Care. 2010;15(1):4–16. doi: 10.3109/13625180903427675.
   PubMed Web of Science ®Google Scholar
• Dude A, Neustadt A, Martins S, et al. Use of withdrawal and unintended pregnancy among females 15–24 years of age. Obstet Gynecol. 2013;122(3):595–600. doi: 10.1097/AOG.0b013e31829d8074.
   PubMed Web of Science ®Google Scholar
• Bradley SEK, Polis CB, Bankole A, et al. Global contraceptive failure rates: who is most at risk? Stud Fam Plann. 2019;50(1):3–24. doi: 10.1111/sifp.12085.
   PubMed Web of Science ®Google Scholar
• World Health Organization Department of Reproductive Health Services. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. Vol. 1. Geneva: World Health Organization FAB; 2000. p. 4.
   Google Scholar
• Grimes DA, Gallo MF, Grigorieva V, et al. Fertility awareness-based methods for contraception. Cochrane Database Syst Rev. 2004;2004(4): CD004860. doi: 10.1002/14651858.CD004860.pub2.
   PubMedGoogle Scholar
• Van der Wijden C, Manion C. Lactational amenorrhoea method for family planning. Cochrane Database Syst Rev. 2015;2015(10):CD001329. doi: 10.1002/14651858.CD001329.PUB2.
   PubMedGoogle Scholar
• Delvoye, P, Demaegd, M, Robyn, C, Uwayitu-Nyampeta, (1978) Serum prolactin, gonadotropins, and estradiol in menstruating and amenorrheic mothers during two years’ lactation.Am J Obstet Gynecol, 6130:635–639. doi: 10.1016/0002-9378(78)90319-8.
   PubMed Web of Science ®Google Scholar
• Perez A, Vela P, Masnick GS, et al. First ovulation after childbirth: the effect of breast-feeding. Am J Obstet Gynecol. 1972;114(8):1041–1047. doi: 10.1016/0002-9378(72)90866-6.
   PubMed Web of Science ®Google Scholar
• Labbok MH. Postpartum sexuality and the lactational amenorrhea method for contraception. Clin Obstet Gynecol. 2015;58(4):915–927. doi: 10.1097/GRF.0000000000000154.
   PubMed Web of Science ®Google Scholar
• Von Hertzen H. The world health organization multinational study of breast-feeding and lactational amenorrhea. III. Pregnancy during breast-feeding. Fertil Steril. 1999;72:431–440. doi: 10.1016/S0015-0282(99)00274-5.
   PubMed Web of Science ®Google Scholar
• Billings JJ. Natural family planning. Med J Aust. 1978;2:436–436. doi: 10.5694/j.1326-5377.1978.tb76840.x.
   PubMed Web of Science ®Google Scholar
• Hume K. Fertility awareness in the 1990s – The billings ovulation method of natural family planning, its scientific basis, practical application and effectiveness. Adv Contracept. 1991;7(2–3):301–311. doi: 10.1007/BF01849421.
   PubMedGoogle Scholar
• World Health Organization. A prospective multicentre trial of the ovulation method of natural family planning. II. The effectiveness phase. Fertil Steril. 1981;536:591–598. doi: 10.1016/s0015-0282(16)45856-5.
   PubMed Web of Science ®Google Scholar
• Frank-Herrmann P, Heil J, Gnoth C, et al. The effectiveness of a fertility awareness based method to avoid pregnancy in relation to a couple’s sexual behaviour during the fertile time: a prospective longitudinal study. Hum Reprod. 2007;22(5):1310–1319. doi: 10.1093/humrep/dem003.
   PubMed Web of Science ®Google Scholar
• Rossier C, Senderowicz L, Soura A. Do natural methods count? Underreporting of natural contraception in urban Burkina Faso. Stud Fam Plann. 2014;45(2):171–182. doi: 10.1111/j.1728-4465.2014.00383.x.
   PubMed Web of Science ®Google Scholar
• Polis CB, Jones RK. Multiple contraceptive method use and prevalence of fertility awareness based method use in the United States, 2013–2015. Contraception. 2018;98(3):188–192. doi: 10.1016/j.contraception.2018.04.013.
   PubMed Web of Science ®Google Scholar
• Turner JV. Misrepresentation of contraceptive effectiveness rates for fertility awareness methods of family planning. J Obstet Gynaecol Res. 2021;47(7):2271–2277. doi: 10.1111/jog.14593.
   PubMed Web of Science ®Google Scholar
• Peragallo Urrutia R, Polis CB, Jensen ET, et al. Effectiveness of fertility awareness–based methods for pregnancy prevention. Obstet Gynecol. 2018;132(3):591–604. doi: 10.1097/AOG.0000000000002784.
   PubMed Web of Science ®Google Scholar
• Trussell J, Grummer-Strawn L. Further analysis of contraceptive failure of the ovulation method. Am J Obstet Gynecol. 1991;165(6 Pt 2):2054–2059. doi: 10.1016/S0002-9378(11)90581-X.
   PubMed Web of Science ®Google Scholar
• Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397–404. doi: 10.1016/j.contraception.2011.01.021.
   PubMed Web of Science ®Google Scholar
• Nilsson A, Ahlborg T, Bernhardsson S. Use of non-medical contraceptive methods: a survey of women in Western Sweden. Eur J Contracept Reprod Health Care. 2018;23(6):400–406. doi: 10.1080/13625187.2018.1541079.
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46 (Suppl 1):S7–S16. doi: 10.1016/j.maturitas.2003.09.014.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008;61(1-2):151–157. doi: 10.1016/j.maturitas.2008.11.011.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006;12(2):169–178. doi: 10.1093/humupd/dmi046.
   PubMed Web of Science ®Google Scholar
• Bozdag G, Yildiz BO. Combined oral contraceptives in polycystic ovary syndrome. Indications and cautions. Polycystic Ovary Syndr. 2012;40:115–127. doi: 10.1159/000341823.
   Google Scholar
• Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24. doi: 10.1016/j.beem.2012.09.004.
   PubMed Web of Science ®Google Scholar
• Goldzieher JW, Brody SA. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol. 1990;163(6 Pt 2):2114–2119. doi: 10.1016/0002-9378(90)90550-Q.
   PubMed Web of Science ®Google Scholar
• Yildiz BO. Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100(3):794–802. doi: 10.1210/jc.2014-3196.
   PubMed Web of Science ®Google Scholar
• Kuhnz W, Blode H, Zimmermann H. Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens. In: Oettel M, Schillinger E, editors Handbook of experimental pharmacology, estrogens and antiestrogens II. Vol. 135. Berlin: Springer Verlag; 1993. p. 261–322.
   Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8 (Suppl 1):3–63. doi: 10.1080/13697130500148875.
   PubMed Web of Science ®Google Scholar
• Junge W, Mellinger U, Parke S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive. Clin Drug Investig. 2011;31(8):573–584. doi: 10.2165/11590220-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Gaussem P, Alhenc-Gelas M, Thomas J-L, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. Thromb Haemost. 2011;105(3):560–567. doi: 10.1160/TH10-05-0327.
   PubMed Web of Science ®Google Scholar
• Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011;16(6):430–443. doi: 10.3109/13625187.2011.614029.
   PubMed Web of Science ®Google Scholar
• Borgelt LM, Martell CW. Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther. 2012;34(1):37–55. doi: 10.1016/j.clinthera.2011.11.006.
   PubMed Web of Science ®Google Scholar
• Abot A, Fontaine C, Buscato M, et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014;6(10):1328–1346. doi: 10.15252/emmm.201404112.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Morimont L, Gaspard U, et al. Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation. Thromb Res. 2022; doi: 10.1016/j.thromres.2022.09.007.
   PubMedGoogle Scholar
• Benoit T, Valera M-C, Fontaine C, et al. Estetrol, a fetal selective estrogen receptor modulator, acts on the vagina of mice through nuclear estrogen receptor α activation. Am J Pathol. 2017;187(11):2499–2507. doi: 10.1016/j.ajpath.2017.07.013.
   PubMed Web of Science ®Google Scholar
• Giretti MS, Montt Guevara MM, Cecchi E, et al. Effects of estetrol on migration and invasion in T47-D breast cancer cells through the actin cytoskeleton. Front Endocrinol (Lausanne). 2014;5:80. doi: 10.3389/fendo.2014.00080.
   PubMed Web of Science ®Google Scholar
• Valéra MC, Noirrit-Esclassan E, Dupuis M, et al. Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis. Mol Cell Endocrinol. 2018;477:132–139. doi: 10.1016/j.mce.2018.06.010.
   PubMed Web of Science ®Google Scholar
• Van Vliet HA, Grimes DA, Lopez LM, et al. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2006;2006(3):CD002032. doi: 10.1002/14651858.CD002032.pub2.
   PubMedGoogle Scholar
• Van Vliet HA, Raps M, Lopez LM, et al. Quadriphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011;2011(11):CD009038. doi: 10.1002/14651858.CD009038.pub2.
   PubMed Web of Science ®Google Scholar
• van Heusden AM, Fauser BCJM. Residual ovarian activity during oral steroid contraception. Hum Reprod Update. 2002;8(4):345–358. doi: 10.1093/humupd/8.4.345.
   PubMed Web of Science ®Google Scholar
• Roumen FJME, Apter D, Mulders TMT, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod. 2001;16(3):469–475. doi: 10.1093/humrep/16.3.469.
   PubMed Web of Science ®Google Scholar
• Goa KL, Warner GT, Easthope SE. Transdermal ethinylestradiol/norelgestromin. Treat Endocrinol. 2003;2(3):191–206. doi: 10.2165/00024677-200302030-00005.
   PubMedGoogle Scholar
• Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75-μg desogestrel-only contraceptive pill (cerazette®) after scheduled 12-h delays in tablet intake. Contraception. 2005;71(1):8–13. doi: 10.1016/j.contraception.2004.07.016.
   PubMed Web of Science ®Google Scholar
• Regidor P-A, Colli E. Drospirenone 4 mg in a 24/4 regimen maintains inhibition of ovulation even after a 24-h delay pill intake - Pharmacological aspects and comparison to other progestin-only pills. Eur Rev Med Pharmacol Sci. 2022;26:1994–1999. doi: 10.26355/eurrev_202203_28348.
   PubMed Web of Science ®Google Scholar
• Teal S, Edelman A. Contraception selection, effectiveness, and adverse effects: a review. Jama. 2021;326(24):2507–2518. doi: 10.1001/jama.2021.21392.
   PubMed Web of Science ®Google Scholar
• Trussell J. Methodological pitfalls in the analysis of contraceptive failure. Stat Med. 1991;10(2):201–220. doi: 10.1002/sim.4780100206.
   PubMed Web of Science ®Google Scholar
• Vaughan B, Trussell J, Kost K, et al. Discontinuation and resumption of contraceptive use: results from the 2002 national survey of family growth. Contraception. 2008;78(4):271–283. doi: 10.1016/j.contraception.2008.05.007.
   PubMed Web of Science ®Google Scholar
• McNicholas C, Madden T, Secura G, et al. The contraceptive CHOICE project round Up. Clin Obstet Gynecol. 2014;57(4):635–643. doi: 10.1097/GRF.0000000000000070.
   PubMed Web of Science ®Google Scholar
• Iseyemi A, Zhao Q, McNicholas C, et al. Socioeconomic status as a risk factor for unintended pregnancy in the contraceptive CHOICE project. Obstet Gynecol. 2017;130(3):609–615. doi: 10.1097/AOG.0000000000002189.
   PubMed Web of Science ®Google Scholar
• Bradley LD, Gueye N-A. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol. 2016;214(1):31–44. doi: 10.1016/j.ajog.2015.07.044.
   PubMed Web of Science ®Google Scholar
• Qin J, Yang T, Kong F, et al. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case–control studies. Arch Gynecol Obstet. 2013;288(1):139–148. doi: 10.1007/s00404-013-2797-9.
   PubMed Web of Science ®Google Scholar
• Sangkomkamhang US, Lumbiganon P, Pattanittum P. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy). Cochrane Database Syst Rev. 2020;11(11):CD008994. doi: 10.1002/14651858.CD008994.pub3.
   PubMedGoogle Scholar
• Vercellini P, Viganò P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–275. doi: 10.1038/nrendo.2013.255.
   PubMed Web of Science ®Google Scholar
• Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet. 2015;292(1):37–43. doi: 10.1007/s00404-015-3641-1.
   PubMed Web of Science ®Google Scholar
• Timby E, Bäckström T, Nyberg S, et al. Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls—a pilot study. Psychopharmacology (Berl). 2016;233(11):2109–2117. doi: 10.1007/s00213-016-4258-1.
   PubMed Web of Science ®Google Scholar
• Carlini SV, Lanza di Scalea T, McNally ST, et al. Management of premenstrual dysphoric disorder: a scoping review. Int J Womens Health. 2022;14:1783–1801. doi: 10.2147/IJWH.S297062.
   PubMed Web of Science ®Google Scholar
• Teede H, Misso M, Costello M, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018; 2018.
   Google Scholar
• Matheson E, Bain J. Hirsutism in women. Am Family Phys. 2019;100:168–175.
   PubMedGoogle Scholar
• The European Society of Human Reproduction and Embryology (ESHRE). Management of women with premature ovarian insufficiency - guideline of the European society of human reproduction and embryology. ESHRE; 2015;2015:1–161.
   Google Scholar
• Gonçalves CR, Vasconcellos AS, Rodrigues TR, et al. Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis. Reprod Biomed Online. 2022;44(6):1143–1157. doi: 10.1016/j.rbmo.2022.02.006.
   PubMed Web of Science ®Google Scholar
• Klein DA, Paradise SL, Reeder RM. Amenorrhea: a systematic approach to diagnosis and management. Am Family Phys. 2019;100:39–48.
   PubMed Web of Science ®Google Scholar
• Gompel A, Ramirez I, Bitzer J, European Society of Contraception Expert Group on Hormonal Contraception. Contraception in cancer survivors–an expert review part I. Breast and gynaecological cancers. Eur J Contracept Reprod Health Care. 2019;24(3):167–174. doi: 10.1080/13625187.2019.1602721.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use, 5th ed. Geneva: World Health Organization. Department of Reproductive Health and Research. 2015.
   Google Scholar
• Abusal F, Aladwan M, Alomari Y, et al. Oral contraceptives and colorectal cancer risk - a meta-analysis and systematic review. Ann Med Surg (Lond). 2022;83:104254. doi: 10.1016/j.amsu.2022.104254.
   PubMedGoogle Scholar
• Bahamondes L, Valeria Bahamondes M, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update. 2015;21(5):640–651. doi: 10.1093/humupd/dmv023.
   PubMed Web of Science ®Google Scholar
• Roach REJ, Helmerhorst FM, Lijfering WM, et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;8:CD011054. doi: 10.1002/14651858.CD011054.
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. Obstet Gynecol Surv. 2012;67(10):640–641. doi: 10.1097/01.ogx.0000422965.64164.ac.
   Web of Science ®Google Scholar
• Schwingl PJ, Shelton J. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives. Contraception. 1997;55(3):125–129. doi: 10.1016/s0010-7824(97)00026-7.
   PubMed Web of Science ®Google Scholar
• Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception. 2007;75(5):328–336. doi: 10.1016/j.contraception.2006.12.018.
   PubMed Web of Science ®Google Scholar
• Dragoman MV, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018;141(3):287–294. doi: 10.1002/ijgo.12455.
   PubMed Web of Science ®Google Scholar
• Soares GM, Vieira CS, De Paula Martins W, et al. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. Int J Clin Pract. 2009;63(1):160–169. doi: 10.1111/j.1742-1241.2008.01877.x.
   PubMed Web of Science ®Google Scholar
• Farris M, Bastianelli C, Rosato E, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis. Expert Rev Clin Pharmacol. 2017;10(10):1129–1144. doi: 10.1080/17512433.2017.1356718.
   PubMed Web of Science ®Google Scholar
• Kluft C, Zimmerman Y, Mawet M, et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. Contraception. 2017;95(2):140–147. doi: 10.1016/j.contraception.2016.08.018.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Klipping C, Duijkers I, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 2020;102(6):396–402. doi: 10.1016/j.contraception.2020.08.015.
   PubMed Web of Science ®Google Scholar
• Pfeifer S, Butts S, Dumesic D, et al. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017;107(1):43–51. doi: 10.1016/j.fertnstert.2016.09.027.
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Rodriguez-Martinez MA, Spoletini I, et al. Obesity and contraceptive use: impact on cardiovascular risk. ESC Heart Fail. 2022;9(6):3761–3767. doi: 10.1002/ehf2.14104.
   PubMed Web of Science ®Google Scholar
• Tepper NK, Whiteman MK, Marchbanks PA, et al. Progestin-only contraception and thromboembolism: a systematic review. Contraception. 2016;94(6):678–700. doi: 10.1016/j.contraception.2016.04.014.
   PubMed Web of Science ®Google Scholar
• de Medeiros SF. Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome. Reprod Biol Endocrinol. 2017;15(1):93. doi: 10.1186/s12958-017-0313-y.
   PubMedGoogle Scholar
• Melo A, Reis R, Ferriani R, et al. Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits. Open Access J Contracept. 2017;8:13–23. doi: 10.2147/oajc.s85543.
   PubMedGoogle Scholar
• Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618. doi: 10.1093/humrep/dey256.
   PubMed Web of Science ®Google Scholar
• Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception. 2016;94(3):280–287. doi: 10.1016/j.contraception.2015.08.002.
   PubMed Web of Science ®Google Scholar
• Fotherby K. Oral contraceptives and lipids. BMJ. 1989;298(6680):1049–1050. doi: 10.1136/bmj.298.6680.1049.
   PubMedGoogle Scholar
• van Rooijen M, von Schoultz B, Silveira A, et al. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am J Obstet Gynecol. 2002;186(1):44–48. doi: 10.1067/mob.2002.119179.
   PubMed Web of Science ®Google Scholar
• Carmina E. Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. J Endocrinol Investig. 2013;36:358–363. doi: 10.3275/8882.
   PubMed Web of Science ®Google Scholar
• Bastianelli C, Farris M, Rosato E, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism. Expert Rev Clin Pharmacol. 2017;10(3):315–326. doi: 10.1080/17512433.2017.1271708.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Cagnacci A, Chabbert-Buffet N, et al. A novel estetrol-containing combined oral contraceptive: european expert panel review. Eur J Contracept Reprod Health Care. 2022;27(5):373–383. doi: 10.1080/13625187.2022.2093850.
   PubMed Web of Science ®Google Scholar
• Halperin IJ, Kumar S, Stroup S, et al. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum Reprod. 2011;26(1):191–201. doi: 10.1093/humrep/deq301.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2014;2014(4):CD006133. doi: 10.1002/14651858.CD006133.pub5.
   PubMed Web of Science ®Google Scholar
• Trémollieres F. Impact of oral contraceptive on bone metabolism. Best Pract Res Clin Endocrinol Metab. 2013;27(1):47–53. doi: 10.1016/j.beem.2012.09.002.
   PubMed Web of Science ®Google Scholar
• Bonjour J-P, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab. 1991;73(3):555–563. doi: 10.1210/jcem-73-3-555.
   PubMed Web of Science ®Google Scholar
• Sabatier J-P, Guaydier-Souquìeres G, Laroche D, et al. Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10–24 years of age. Osteoporos Int. 1996;6(2):141–148. doi: 10.1007/BF01623938.
   PubMed Web of Science ®Google Scholar
• Liu SL, Lebrun CM. Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review. Br J Sports Med. 2006;40(1):11–24. doi: 10.1136/bjsm.2005.020065.
   PubMed Web of Science ®Google Scholar
• Gersten J, Hsieh J, Weiss H, et al. Effect of extended 30 μg ethinyl estradiol with continuous low-dose ethinyl estradiol and cyclic 20 μg ethinyl estradiol oral contraception on adolescent bone density: a randomized trial. J Pediatr Adolesc Gynecol. 2016;29(6):635–642. doi: 10.1016/j.jpag.2016.05.012.
   PubMed Web of Science ®Google Scholar
• Grandi G, Napolitano A, Cagnacci A. Metabolic impact of combined hormonal contraceptives containing estradiol. Expert Opin Drug Metab Toxicol. 2016;12(7):779–787. doi: 10.1080/17425255.2016.1190832.
   PubMed Web of Science ®Google Scholar
• Mawet M, Maillard C, Klipping C. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur J Contracept Reprod Health Care. 2015;20:463–475. doi: 10.3109/13625187.2015.1068934.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF, et al. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev. 2014;24(6):CD006033. doi: 10.1002/14651858.CD006033.pub5.
   PubMed Web of Science ®Google Scholar
• Hadji P, Colli E, Regidor P. Bone health in estrogen-free contraception. Osteoporos Int. 2019;30(12):2391–2400. doi: 10.1007/s00198-019-05103-6.
   PubMed Web of Science ®Google Scholar
• Finlay-Schultz J, Sartorius CA. Steroid hormones, steroid receptors, and breast cancer stem cells. J Mammary Gland Biol Neoplasia. 2015;20(1-2):39–50. doi: 10.1007/s10911-015-9340-5.
   PubMed Web of Science ®Google Scholar
• Cavalieri E, Rogan E. The molecular etiology and prevention of estrogen-initiated cancers. Mol Aspects Med. 2014;36:1–55. doi: 10.1016/j.mam.2013.08.002.
   PubMed Web of Science ®Google Scholar
• Mørch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228–2239. doi: 10.1056/NEJMoa1700732.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713–1727. doi: 10.1016/s0140-6736(96)90806-5.
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Pike MC. Hormonal contraception and breast cancer. Contraception. 2018;98(3):171–173. doi: 10.1016/j.contraception.2018.05.002.
   PubMed Web of Science ®Google Scholar
• van Bommel MHD, IntHout J, Veldmate G, et al. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum Reprod Update. 2022;29(2):197–217.
   Web of Science ®Google Scholar
• Gallez A, Dias Da Silva I, Wuidar V, et al. Estetrol and mammary gland: friends or foes? J Mammary Gland Biol Neoplasia. 2021;26(3):297–308. doi: 10.1007/s10911-021-09497-0.
   PubMed Web of Science ®Google Scholar
• Samson M, Porter N, Orekoya O, et al. Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat. 2016;155(1):3–12. doi: 10.1007/s10549-015-3663-1.
   PubMed Web of Science ®Google Scholar
• Estrada-Camarena E, López-Rubalcava C, Vega-Rivera N, et al. Antidepressant effects of estrogens: a basic approximation. Behav Pharmacol. 2010;21(5-6):451–464. doi: 10.1097/FBP.0b013e32833db7e9.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Fidecicchi T. Hormonal contraception and depression: updated evidence and implications in clinical practice. Clin Drug Investig. 2020;40(12):1097–1106. doi: 10.1007/s40261-020-00966-8.
   PubMed Web of Science ®Google Scholar
• Vigil P, del Río JP, Carrera B, et al. Influence of sex steroid hormones on the adolescent brain and behavior: an update. Linacre Q. 2016;83(3):308–329. doi: 10.1080/00243639.2016.1211863.
   PubMed Web of Science ®Google Scholar
• Bengtsdotter H, Lundin C, Gemzell Danielsson K, et al. Ongoing or previous mental disorders predispose to adverse mood reporting during combined oral contraceptive use. Eur J Contracept Reprod Health Care. 2018;23(1):45–51. doi: 10.1080/13625187.2017.1422239.
   PubMed Web of Science ®Google Scholar